Drug news & perspectives最新文献_第3页

Therapeutics that directly increase SMN expression to treat spinal muscular atrophy. 直接增加SMN表达治疗脊髓性肌萎缩的疗法。

Drug news & perspectives Pub Date : 2010-10-01 DOI: 10.1358/dnp.2010.23.8.1507295

Monir Shababi, Virginia B Mattis, Christian L Lorson

引用次数: 15

The rise and fall of Dimebon. Dimebon的兴衰。

Drug news & perspectives Pub Date : 2010-10-01 DOI: 10.1358/dnp.2010.23.8.1500435

Ilya Bezprozvanny

{"title":"The rise and fall of Dimebon.","authors":"Ilya Bezprozvanny","doi":"10.1358/dnp.2010.23.8.1500435","DOIUrl":"https://doi.org/10.1358/dnp.2010.23.8.1500435","url":null,"abstract":"Dimebon (latrepirdine) was developed and used in Russia as an over-the-counter oral antihistamine for allergy treatment. In the early 1990s, Dimebon was characterized as a low-affinity NMDA receptor antagonist by Dr. Sergey Bachurin and his colleagues. An initial small-scale, open-label trial of Dimebon in 14 Alzheimer's disease (AD) patients demonstrated potential efficacy. Dimebon was then patented for the treatment of neurodegenerative disorders and licensed by Medivation. Extremely promising results were obtained in a double-blind, placebo-controlled, phase II AD trial in 183 patients; however, a phase II trial of Dimebon in 91 Huntington's disease patients was much less successful. Recently, a phase III AD trial of Dimebon in 598 patients failed to result in any significant improvement in primary or secondary outcomes. The failure of Dimebon may be in large part due to insufficient understanding of its mechanism of action. The NMDA receptor blocking activity of Dimebon is too weak to be physiologically relevant, while the proposed \"novel mitochondrial mechanism of action\" lacks credible scientific evidence or a molecular target. Independent studies indicate that the clinical effects of Dimebon most likely result from inhibition of histamine H₁ and serotonin 5-HT₆ receptors. Careful preclinical studies of novel potential therapies are needed to minimize chances of making similar costly mistakes in the future.","PeriodicalId":11325,"journal":{"name":"Drug news & perspectives","volume":"23 8","pages":"518-23"},"PeriodicalIF":0.0,"publicationDate":"2010-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922928/pdf/nihms417273.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29429466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 89

Targeting IKKβ for the treatment of rheumatoid arthritis. 靶向IKKβ治疗类风湿性关节炎。

Drug news & perspectives Pub Date : 2010-10-01 DOI: 10.1358/dnp.2010.23.8.1447844

Paul Bamborough, Mary A Morse, Keith P Ray

引用次数: 20

Chemical & biological therapeutic approaches to neurological disorders. 神经系统疾病的化学和生物治疗方法。

Drug news & perspectives Pub Date : 2010-10-01 DOI: 10.1358/dnp.2010.23.8.1524353

Irene François

引用次数: 0

Brown adipose tissue: a promising target to combat obesity. 棕色脂肪组织:对抗肥胖的一个有希望的目标。

Drug news & perspectives Pub Date : 2010-09-01 DOI: 10.1358/dnp.2010.23.7.1487083

Cecile Vernochet, Meghan E McDonald, Stephen R Farmer

引用次数: 24

The search for biomarkers for attention deficit/hyperactivity disorder. 寻找注意力缺陷/多动障碍的生物标志物。

Drug news & perspectives Pub Date : 2010-09-01 DOI: 10.1358/dnp.2010.23.7.1472296

Deeann Wallis

{"title":"The search for biomarkers for attention deficit/hyperactivity disorder.","authors":"Deeann Wallis","doi":"10.1358/dnp.2010.23.7.1472296","DOIUrl":"https://doi.org/10.1358/dnp.2010.23.7.1472296","url":null,"abstract":"The main characteristic of attention deficit/hyperactivity disorder (ADHD) is a persistent pattern of inattention and/or hyperactivity-impulsivity which is more frequent and severe than is usually expected in individuals at a comparable level of development. ADHD is estimated to affect approximately 5.29% of school-aged children and is therefore the most common childhood onset psychological disorder. A conservative estimate of the annual societal cost of illness for ADHD in childhood and adolescence is USD 42.5 billion in the U.S. alone. Global sales of ADHD medicines could reach USD 4.3 billion by 2012. Despite the prevalence, high heritability and costs of ADHD, biological markers do not exist. Such biomarkers are in high demand as they would help eliminate the subjective diagnoses based on interviews and potentially allow for earlier diagnosis and personalized medicine. Lack of markers likely stems from several factors that complicate ADHD research and the assessment of pharmacological responses. This review analyses complicating factors in defining ADHD phenotype and etiology, identifying specific diagnostic markers and the difficulties in the assessment of pharmacogenomic markers. The dopamine transporter (DAT1) genotype and methylphenidate (MPH) response are detailed as an example of a biomarker. A recent report of a novel ADHD gene and its possible role as a biomarker is explored. Finally, suggestions for strategies and study designs for future research for the definition of effective ADHD biomarkers are made.","PeriodicalId":11325,"journal":{"name":"Drug news & perspectives","volume":"23 7","pages":"438-49"},"PeriodicalIF":0.0,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29296565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 23

Molecule of the month. Lasmiditan hydrochloride. 本月分子。Lasmiditan 盐酸盐。

Drug news & perspectives Pub Date : 2010-09-01 DOI: 10.1358/dnp.2010.23.7.1538344

引用次数: 0

A summary on stem cell research: a report on the 8th Annual Meeting of the International Society for Stem Cell Research. 干细胞研究综述:第八届国际干细胞研究学会年会报告。

Drug news & perspectives Pub Date : 2010-09-01 DOI: 10.1358/dnp.2010.23.7.1519653

Gaetano Romano

引用次数: 1

Targeting Wee1-like protein kinase to treat cancer. 靶向wee1样蛋白激酶治疗癌症。

Drug news & perspectives Pub Date : 2010-09-01 DOI: 10.1358/dnp.2010.23.7.1490760

Anastasios Stathis, Amit Oza

{"title":"Targeting Wee1-like protein kinase to treat cancer.","authors":"Anastasios Stathis, Amit Oza","doi":"10.1358/dnp.2010.23.7.1490760","DOIUrl":"https://doi.org/10.1358/dnp.2010.23.7.1490760","url":null,"abstract":"New anticancer agents are needed in order to overcome the resistance of cancer cells to standard chemotherapy. At present, many of the molecular events that drive the malignant transformation and progression have been identified and there is optimism that the development of agents that specifically target such events will improve treatment outcomes. Cancer cells present common alterations in components of pathways that are involved in the normal cell cycle regulation and in mechanisms of DNA damage repair. Wee1-like protein kinase is a tyrosine kinase with a key role as an inhibitory regulator of the G2/M checkpoint that precedes entry into mitosis. Abrogation of this checkpoint through Wee1 inhibition may result in increased antitumor activity of agents that cause DNA damage such as radiation therapy or some cytotoxic agents. This has been confirmed in preclinical studies and results of clinical studies evaluating a Wee1 inhibitor are awaited to establish its activity in combination with chemotherapy. Here we review the role of Wee1 tyrosine kinase in the control of the G2/M checkpoint and the effects of G2/M checkpoint abrogation through Wee1 inhibition. We present results of preclinical studies with Wee1 inhibitors and the results of the first clinical trial recently reported, evaluating MK-1775, a small-molecule inhibitor of Wee1.","PeriodicalId":11325,"journal":{"name":"Drug news & perspectives","volume":"23 7","pages":"425-9"},"PeriodicalIF":0.0,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29299969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 39

Therapeutic potential of nitric oxide modulation in ocular diseases. 一氧化氮调节在眼部疾病中的治疗潜力。

Drug news & perspectives Pub Date : 2010-09-01 DOI: 10.1358/dnp.2010.23.7.1484488

Filippo Drago, Claudio Bucolo

引用次数: 16